With the developing knowledge on genetic variants influencing pharmacokinetics and/or
pharmacodynamics of frequently applied drugs, multiple providers are now offering PGx
assessment using DNA isolated from buccal swaps. One product is
Stratipharm (https://www.stratipharm.de) that offers genotyping (based on the DNA obtained from a buccal swap) in combination with sophisticated evidence-based interpretation of the genotype. The test system covers almost 100 genetic variants corresponding to 30 genes of pharmacogenetic relevance.
In an observational study over 3 years the primary objective is the compilation of case reports, where pharmacogenetic testing is applied to determine the hereditable component of the patient’s susceptibility to experience therapy failure and/or adverse drug reactions. The experience with the compiled cases will be basis for the development of a reliable standard of procedure for pharmacogenetic testing in the community pharmacy.